<DOC>
	<DOCNO>NCT01743807</DOCNO>
	<brief_summary>This phase I trial investigational drug call GNKG168 patient relapse refractory acute lymphoblastic leukemia ( ALL ) acute myelogenous leukemia ( AML ) morphologic remission positive Minimum Residual Disease ( MRD ) . GNKG168 Toll-like receptor ( TLR ) agonist . TLR agonists novel approach stimulate effective anti-tumor immune response able stimulate innate adaptive immune response . There two stratum i.e patient receive hematopoietic stem cell transplant ( HSCT ) patient never undergone HSCT . GNKG168 administer 60 min iv infusion . One 14-day cycle consist 5-day treatment follow 9 day-rest . Patients receive 2 cycle evaluation . The primary objective determine maximum tolerate dose GNKG168 relapse ALL AML patient .</brief_summary>
	<brief_title>Phase I Study GNKG168 Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients must ≥1 ≤ 21 year age originally diagnose ALL AML . Diagnosis 1 . Patients must previously histologically confirm ALL AML original diagnosis previous relapse . 2 . Patients must complete remission ( CR ) less 5 % blast bone marrow . PostHSCT patient first great CR Patients never receive HSCT second great CR c. Patient must detectable MRD ( ≥0.01 % ) flow cytometry confirm Brent Woods ' lab . Results must available time enrollment . Karnofsky ≥ 50 % patient &gt; 16 year age Lansky ≥ 50 % patient ≤16 year age . ( See Appendix I Performance Scales ) Patients must fully recover acute toxic effect prior anticancer therapy . At least 14 day must elapse since treatment systemic chemotherapy include highdose steroid ( prednisone &gt; 0.5 mg/kg equivalent ) , radiotherapy , biological therapy investigational therapy . ( Note : lowdose steroid ; prednisone ≤0.5 mg/kg/day equivalent allow . ) Patients never Hematopoietic Stem Cell Transplant ( HSCT ) must suitable candidate HSCT . Previous Hematopoietic Stem Cell Transplant : 1 . Patients receive HSCT eligible . 2 . Patients receive donor lymphocyte infusion ( DLI ) eligible . 3 . At least 60 day must elapse last DLI . 4 . Must ≥95 % donor Tcell chimerism . 5 . Patients must immune suppression drug 7 day study entry . ( least 2 week highdose steroid , i.e . prednisone &gt; 0.5 mg/kg equivalent ; see section 3.3.4 b ) ( Note ; lowdose steroid ; prednisone ≤0.5 mg/kg/day equivalent allow . ) Patients must serum creatinine less equal 1.5 x institutional upper limit normal accord age . Patient 's alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) must less equal 3 x institutional upper limit normal . Patient 's total bilirubin must less equal 1.5 x institutional upper limit normal . Patient must shorten fraction &gt; 27 % ejection fraction &gt; 45 % echocardiogram ( ECHO ) multigated radionuclide angiography ( MUGA ) . Female patient childbearing potential must negative urine serum pregnancy test confirm prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study . Patients must absolute neutrophil count &gt; 1000/dL , platelet &gt; 100,000/dL AND absolute lymphocyte count &gt; 200 decreasing . Patients previous HSCT may platelet count &gt; 50,000/dL . Active grade 2 high acute GVHD time study entry . Active chronic GVHD ( moderate severe ) . See Appendix 2 Chronic GVHD Grading . Plan donor lymphocyte infusion study period . Need immunosuppressive medication include highdose corticosteroid ( prednisone &gt; 0.5 mg/kg equivalent ) ( Note : lowdose steroid ; prednisone ≤0.5 mg/kg/day equivalent allow . ) Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Patient exclude currently receive investigational drug . Patients exclude plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Patients exclude significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance prescribe protocol therapy , interfere consent , study participation , follow , interpretation study result . Patients central nervous system 3 disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Minimal Residual Disease</keyword>
	<keyword>MRD</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>AML</keyword>
	<keyword>GNKG168</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Childhood</keyword>
</DOC>